Joseph Schwartz

Anupam Rama

Gena Wang

Mark Connolly

Allison Bratzel

Gbola Amusa

Maneka Mirchandaney

Maury Raycroft

- Solid Biosciences, a precision genetic medicine company, is advancing three main gene therapy programs for Duchenne muscular dystrophy (DMD), Friedreich's ataxia (FA), and CPVT (catecholaminergic polymorphic ventricular tachycardia).  **[1707502_tx_380773_0]** 
- For its DMD program (SLB-101), **15 boys have been dosed** with a **positive safety profile**.  **[1707502_tx_380773_2]**  The company anticipates an FDA meeting in **Q4 2025** to discuss accelerated approval, with a potential Biologics License Application (BLA) filing by **end of 2026**.  **[1707502_tx_380773_4]** **[1707502_tx_380773_5]** 
- Initial patient dosing for both the Friedreich's ataxia and CPVT programs is expected in **Q4 2025**, with first results for FA anticipated in the **first half of 2026**.  **[1707502_tx_380773_8]** **[1707502_tx_380773_9]** **[1707502_tx_380773_10]**

Solid Biosciences (SLDB)